CORPHED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CORPHED (CORPHED).
Corbined (idarucizumab) is a humanized monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant effect. It acts as a specific reversal agent for dabigatran.
| Metabolism | Idarucizumab is a monoclonal antibody fragment; it is degraded into small peptides and amino acids via catabolic pathways. No significant metabolism by CYP enzymes. |
| Excretion | Renal (70-80% as unchanged drug), biliary/fecal (20-30%) |
| Half-life | Terminal half-life 3-4 hours; prolonged in renal impairment (up to 15 hours) |
| Protein binding | 20-30% bound to albumin |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 65-75%; Intramuscular: 75-85% |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 10-15 minutes; Intravenous: <5 minutes |
| Duration of Action | Oral: 4-6 hours; Intramuscular: 4-5 hours; Intravenous: 2-4 hours |
| Molecular Weight | 337.45 |
10-20 mg orally twice daily; maximum 60 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-60 mL/min: 50% dose reduction; GFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: contraindicated. |
| Pediatric use | 0.3-0.5 mg/kg orally twice daily; maximum 40 mg/day. |
| Geriatric use | Initiate at 10 mg orally once daily, titrate cautiously to maximum 40 mg/day. |
| 1st trimester | Avoid due to potential teratogenic effects; associated with cardiovascular and CNS malformations in animal studies. |
| 2nd trimester | Avoid; risk of fetal hypoxia and metabolic acidosis due to maternal hypertension and uterine vasoconstriction. |
| 3rd trimester | Avoid; may cause neonatal hypertension, tachycardia, and withdrawal syndrome. |
Clinical note
Comprehensive clinical and safety monograph for CORPHED (CORPHED).
| Placental transfer | Yes, Corphred crosses the placenta readily with fetal concentrations approximately 50-70% of maternal levels based on animal data. |
| Breastfeeding | Corphred is excreted into breast milk in small amounts; however, due to potential cardiovascular effects in neonates, it is generally not recommended during breastfeeding. Alternative agents with better safety profile should be considered. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to Corphred or any componentSevere hypertension (SBP >180 mmHg or DBP >110 mmHg)PheochromocytomaConcurrent use with MAOIs or within 14 days of MAOI therapyHistory of stroke or transient ischemic attackNarrow-angle glaucomaUrinary retention due to prostatic hypertrophy
| Precautions | Thromboembolic risk: Reversal of anticoagulation may expose patients to thrombotic risk; consider reinitiating antithrombotic therapy when appropriate., Hypersensitivity reactions: Monitor for infusion-related reactions. |
| Food/Dietary | Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis with MAOIs if applicable. No specific food interactions with Corphéd alone, but maintain hydration to support blood pressure. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | CORPHED (phenylephrine) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of fetal malformations associated with maternal hypertension and reduced placental perfusion; animal studies have shown teratogenic effects at high doses. During the second and third trimesters, prolonged use may cause uteroplacental insufficiency, fetal hypoxia, and bradycardia. It is recommended to avoid use during pregnancy unless the benefit outweighs the risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate for hypertensive episodes or reflex bradycardia. Assess fetal heart rate during prolonged infusions for signs of fetal distress. In high-dose or continuous intravenous administration, monitor uterine contractility and placental perfusion. Watch for maternal symptoms of hypertension, headache, or arrhythmia. |
| Fertility Effects | There is no conclusive evidence that phenylephrine adversely affects human fertility. Animal studies do not suggest significant reproductive impairment. However, use in assisted reproductive technology (e.g., during oocyte retrieval) is limited due to vasoconstrictive effects on ovarian blood flow. Overall, no specific fertility precautions are required. |
| Clinical Pearls | Corphéd (corphédrine) is a direct-acting α₁-adrenergic agonist used primarily for hypotension during spinal anesthesia. Onset within 1-2 minutes IM. Avoid in hypertensive crisis or MAOI use within 14 days. Monitor BP closely; may cause reflex bradycardia. Use with caution in hyperthyroidism, pheochromocytoma, or severe arteriosclerosis. |
| Patient Advice | This medication is used to raise low blood pressure during certain procedures. · Report any chest pain, severe headache, or irregular heartbeat immediately. · Avoid sudden position changes to prevent dizziness. · Do not use with certain antidepressants (MAOIs) without doctor approval. · Store at room temperature away from light and moisture. |